Pyxis Oncology (NASDAQ:PYXS) Issues Earnings Results, Meets Estimates

Pyxis Oncology (NASDAQ:PYXS) issued its earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32), Zacks reports.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.16 on Tuesday. The stock has a market cap of $68.98 million, a P/E ratio of -1.13 and a beta of 1.11. The stock’s fifty day moving average is $1.37 and its 200 day moving average is $2.42. Pyxis Oncology has a one year low of $0.99 and a one year high of $6.18.

Institutional Trading of Pyxis Oncology

An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE grew its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 20.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,745 shares of the company’s stock after buying an additional 9,062 shares during the period. Bank of America Corp DE owned 0.09% of Pyxis Oncology worth $84,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 39.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PYXS. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. HC Wainwright reissued a “buy” rating and issued a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price target (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.20.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.